Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ernst & Young Reports Accelerated Pharmaceutical Expansion In China

This article was originally published in PharmAsia News

Executive Summary

Ernst & Young recently conducted a survey on 40 high-level executives in 15 leading pharmaceutical companies operating in China. According to the findings, China will be one of the most important growing markets in the next several years thanks to healthcare plan extension and rising wealth, which will increase demand for drugs. Ernst & Young notes that global pharmaceutical firms' expansion of their China businesses reflects the huge development opportunities arising from the local population's growing purchasing power and greater coverage of health insurance, led by a burgeoning middle class. However, the country's commercial complexities will force enterprises to seek more flexible and innovative business models. The report surmises that strength in execution will be especially critical. (Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066993

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel